New Product - Trelegy Ellipta
Fluticasone furoate/umeclidinium (bromide)/vilanterol (trifenatate) (Trelegy Ellipta) represent three classes of medications: a synthetic corticosteroid (an inhaled corticosteroid (ICS)), a long-acting muscarinic receptor antagonist (LAMA), and a selective, long-acting β2-receptor agonist (LABA), respectively. Trelegy Ellipta is indicated for the maintenance treatment of adults with moderate to severe chronic obstructive pulmonary disease (COPD) who require treatment with LAMA + LABA + ICS. Trelegy Ellipta is not indicated for the initiation of therapy in COPD. Trelegy Ellipta is contraindicated in patients with severe milk protein allergy. Trelegy Ellipta is available as a moulded plastic device containing two foil blister strips (each foil strip contains 30 regularly distributed blisters), with one strip containing fluticasone furoate 100 microgram and the other strip containing umeclidinium (bromide) 62.5 microgram and vilanterol (trifenatate) 25 microgram.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629